Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Novo Japan Seeks Thumbs-Up for Sogroya Use in Short Stature
June 28, 2022
- Mitsubishi Tanabe, EditForce Join Forces for Discovery of Gene Therapy in CNS
June 28, 2022
- Kyowa Kirin Gets EU Backing for Crysvita’s Label Expansion into TIO
June 28, 2022
- Kobayashi Kako to Withdraw Marketing License Next April
June 28, 2022
- Daiichi Sankyo CEO Snags 341 Million Yen in FY2021: Securities Filing
June 28, 2022
- Bimzelx as Driver, UCB Set to Derive Half of Global Sales from Immunology Biz
June 28, 2022
- Ex-Wakamoto Chairman Misused 1.7 Million Yen from Company’s Coffers
June 27, 2022
- Takeda to Absorb Nihon Pharmaceutical in October
June 27, 2022
- Ono Chief Pledges to Boost Compliance after Bribery Case
June 24, 2022
- 25 Japan Drug Makers Log Combined 10.7% Growth in FY2021, 12 See Two-Digit Jumps: Tally
June 24, 2022
- JCR Executive Pay Tops 100 Million Yen for First Time in FY2021
June 24, 2022
- Pfizer Curbs Stelues Shipment in Japan on Spike in Demand
June 23, 2022
- EMA Starts Enhertu Review for HER2 Low Breast Cancer
June 23, 2022
- Biosimilars Likely to Gain Further Impetus from Govt Push; Forteo/Enbrel Hit 40% Share, Herceptin 50%-Plus
June 22, 2022
- Alinamin Invites New President from Non-Pharma Sector
June 22, 2022
- Tokyo Wholesaler Slapped with 10-Day Biz Suspension over Fake Triazolam API
June 22, 2022
- Taiho Lifts Shipment Control on Abraxane
June 21, 2022
- ASKA Licenses Korean Rights for Birth Control Pill Drospirenone
June 21, 2022
- Astellas Workforce Down by More than 700: Securities Report
June 21, 2022
- PeptiDream Set to Develop Peptide-RI Conjugates for Refractory Cancers, Eyes No. 1 Spot in Radiotherapy
June 20, 2022
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…